Evaluation of neuroprotective and immunomodulatory properties of mesenchymal stem cells in an ex vivo retinal explant model.
Cellular therapy
Glaucoma
Immunomodulation
Mesenchymal stem cell
Microglia
Neuroprotection
Retinal ganglion cell
Journal
Journal of neuroinflammation
ISSN: 1742-2094
Titre abrégé: J Neuroinflammation
Pays: England
ID NLM: 101222974
Informations de publication
Date de publication:
02 Mar 2022
02 Mar 2022
Historique:
received:
03
11
2021
accepted:
18
02
2022
entrez:
3
3
2022
pubmed:
4
3
2022
medline:
8
4
2022
Statut:
epublish
Résumé
Glaucoma is a blinding degenerative neuropathy in which the death of retinal ganglion cells (RGCs) causes progressive loss of visual field and eventually vision. Neuroinflammation appears to be a key event in the progression and spread of this disease. Thus, microglial immunomodulation represents a promising therapeutic approach in which mesenchymal stem cells (MSCs) might play a crucial role. Their neuroprotective and regenerative potentials have already raised hope in animal models. Yet no definitive treatment has been developed, and some safety concerns have been reported in human trials. In the present study, we investigated the neuroprotective and immunomodulatory properties as well as the safety of MSCs in an ex vivo neuroretina explant model. Labeled rat bone marrow MSCs were placed in coculture with rat retinal explants after optic nerve axotomy. We analyzed the neuroprotective effect of MSCs on RGC survival by immunofluorescence using RBPMS, Brn3a, and NeuN markers. Gliosis and retinal microglial activation were measured by using GFAP, CD68, and ITGAM mRNA quantification and GFAP, CD68, and Iba1 immunofluorescence stainings. We also analyzed the mRNA expression of both 'M1' or classically activated state inflammatory cytokines (TNFα, IL1β, and IL6), and 'M2' or alternatively activated state microglial markers (Arginase 1, IL10, CD163, and TNFAIP6). The number of RGCs was significantly higher in retinal explants cultured with MSCs compared to the control group at Day 7 following the optic nerve axotomy. Retinal explants cultured with MSCs showed a decrease in mRNA markers of gliosis and microglial activations, and immunostainings revealed that GFAP, Iba1, and CD68 were limited to the inner layers of the retina compared to controls in which microglial activation was observed throughout the retina. In addition, MSCs inhibited the M1 phenotype of the microglia. However, edema of the explants was observed in presence of MSCs, with an increase in fibronectin labeling at the surface of the explant corresponding to an epiretinal membrane-like phenotype. Using an ex vivo neuroretina model, we demonstrated a neuroprotective and immunomodulatory effect of MSCs on RGCs. Unfortunately, the presence of MSCs also led to explant edema and epiretinal membrane formation, as described in human trials. Using the MSC secretome might offer the beneficial effects of MSCs without their potential adverse effects, through paracrine signaling.
Sections du résumé
BACKGROUND
BACKGROUND
Glaucoma is a blinding degenerative neuropathy in which the death of retinal ganglion cells (RGCs) causes progressive loss of visual field and eventually vision. Neuroinflammation appears to be a key event in the progression and spread of this disease. Thus, microglial immunomodulation represents a promising therapeutic approach in which mesenchymal stem cells (MSCs) might play a crucial role. Their neuroprotective and regenerative potentials have already raised hope in animal models. Yet no definitive treatment has been developed, and some safety concerns have been reported in human trials. In the present study, we investigated the neuroprotective and immunomodulatory properties as well as the safety of MSCs in an ex vivo neuroretina explant model.
METHODS
METHODS
Labeled rat bone marrow MSCs were placed in coculture with rat retinal explants after optic nerve axotomy. We analyzed the neuroprotective effect of MSCs on RGC survival by immunofluorescence using RBPMS, Brn3a, and NeuN markers. Gliosis and retinal microglial activation were measured by using GFAP, CD68, and ITGAM mRNA quantification and GFAP, CD68, and Iba1 immunofluorescence stainings. We also analyzed the mRNA expression of both 'M1' or classically activated state inflammatory cytokines (TNFα, IL1β, and IL6), and 'M2' or alternatively activated state microglial markers (Arginase 1, IL10, CD163, and TNFAIP6).
RESULTS
RESULTS
The number of RGCs was significantly higher in retinal explants cultured with MSCs compared to the control group at Day 7 following the optic nerve axotomy. Retinal explants cultured with MSCs showed a decrease in mRNA markers of gliosis and microglial activations, and immunostainings revealed that GFAP, Iba1, and CD68 were limited to the inner layers of the retina compared to controls in which microglial activation was observed throughout the retina. In addition, MSCs inhibited the M1 phenotype of the microglia. However, edema of the explants was observed in presence of MSCs, with an increase in fibronectin labeling at the surface of the explant corresponding to an epiretinal membrane-like phenotype.
CONCLUSION
CONCLUSIONS
Using an ex vivo neuroretina model, we demonstrated a neuroprotective and immunomodulatory effect of MSCs on RGCs. Unfortunately, the presence of MSCs also led to explant edema and epiretinal membrane formation, as described in human trials. Using the MSC secretome might offer the beneficial effects of MSCs without their potential adverse effects, through paracrine signaling.
Identifiants
pubmed: 35236378
doi: 10.1186/s12974-022-02418-w
pii: 10.1186/s12974-022-02418-w
pmc: PMC8892697
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
63Informations de copyright
© 2022. The Author(s).
Références
J Vis Exp. 2011 May 12;(51):
pubmed: 21610673
J Neuroinflammation. 2021 Sep 20;18(1):216
pubmed: 34544428
J Ophthalmic Vis Res. 2017 Jan-Mar;12(1):58-64
pubmed: 28299008
Trends Mol Med. 2015 May;21(5):271-3
pubmed: 25945404
Eur J Pharmacol. 2016 Sep 15;787:134-42
pubmed: 27044433
J Neuroinflammation. 2014 Jun 03;11:98
pubmed: 24889886
Sci Rep. 2020 Sep 25;10(1):15808
pubmed: 32978500
Stem Cells Int. 2019 Dec 27;2019:7869130
pubmed: 31949441
Int J Mol Sci. 2021 Jan 14;22(2):
pubmed: 33466583
Invest Ophthalmol Vis Sci. 2019 May 1;60(6):1914-1927
pubmed: 31042799
Front Neuroanat. 2017 Sep 05;11:77
pubmed: 28928639
Cytotherapy. 2015 May;17(5):543-59
pubmed: 25618560
Mol Neurobiol. 2016 Mar;53(2):1181-1194
pubmed: 25598354
World J Stem Cells. 2021 Jun 26;13(6):632-644
pubmed: 34249232
Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3503-12
pubmed: 18408186
Front Neurol. 2021 Mar 16;12:624983
pubmed: 33796062
Exp Eye Res. 2016 Oct;151:38-44
pubmed: 27450912
Prog Retin Eye Res. 2021 Jul;83:100916
pubmed: 33075485
J Comp Neurol. 2014 Apr 15;522(6):1411-43
pubmed: 24318667
Am J Ophthalmol. 2017 May;177:xix-xx
pubmed: 28366429
J Neuroinflammation. 2021 Sep 16;18(1):206
pubmed: 34530842
Clin Exp Immunol. 2017 Apr;188(1):1-11
pubmed: 28108980
J Neurosci. 1994 Jul;14(7):4368-74
pubmed: 8027784
Stem Cell Res Ther. 2021 Jan 9;12(1):52
pubmed: 33422139
Clin Interv Aging. 2013;8:1467-70
pubmed: 24204132
Cell Death Dis. 2020 Sep 23;11(9):793
pubmed: 32968042
Stem Cells Transl Med. 2017 Apr;6(4):1273-1285
pubmed: 28198592
Int J Mol Sci. 2018 Jul 11;19(7):
pubmed: 29997321
Adv Exp Med Biol. 2018;1089:47-57
pubmed: 29774506
Prog Brain Res. 2020;257:99-118
pubmed: 32988476
Blood. 2002 May 15;99(10):3838-43
pubmed: 11986244
Brain. 2014 Feb;137(Pt 2):503-19
pubmed: 24176979
J Cereb Blood Flow Metab. 2018 Aug;38(8):1276-1292
pubmed: 29768965
Brain Res. 2019 Dec 1;1724:146422
pubmed: 31472111
N Engl J Med. 2017 Mar 16;376(11):1047-1053
pubmed: 28296617
Trends Immunol. 2004 Dec;25(12):677-86
pubmed: 15530839
Retin Cases Brief Rep. 2017 Summer;11(3):227-231
pubmed: 27171917
Turk J Ophthalmol. 2018 Feb;48(1):33-38
pubmed: 29576896
Neural Regen Res. 2019 Mar;14(3):391-394
pubmed: 30539803
Stem Cell Rev Rep. 2016 Dec;12(6):654-663
pubmed: 27665290
Cells. 2021 Mar 25;10(4):
pubmed: 33806128
Cells. 2020 Feb 25;9(3):
pubmed: 32106630
BMC Immunol. 2021 Aug 4;22(1):52
pubmed: 34348643
Invest Ophthalmol Vis Sci. 2011 May 17;52(6):3309-20
pubmed: 21345987
Stem Cells Dev. 2017 May 1;26(9):617-631
pubmed: 28186467
Acta Pharmacol Sin. 2013 Jan;34(1):6-7
pubmed: 23262666
Invest Ophthalmol Vis Sci. 1995 Apr;36(5):774-86
pubmed: 7706025
Exp Eye Res. 2019 Sep;186:107722
pubmed: 31302158
Int J Mol Sci. 2020 Dec 07;21(23):
pubmed: 33297577
Doc Ophthalmol. 2021 Aug;143(1):33-38
pubmed: 33469852
Cytotherapy. 2016 Jan;18(1):13-24
pubmed: 26631828
Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2051-9
pubmed: 19933193
Cell Mol Life Sci. 2013 Oct;70(20):3871-82
pubmed: 23456256
Stem Cells. 2015 Oct;33(10):3006-16
pubmed: 26175331
Exp Neurol. 2012 Jul;236(1):34-45
pubmed: 22504112
ASN Neuro. 2015 Aug 26;7(4):
pubmed: 26311075
Cells. 2021 Mar 07;10(3):
pubmed: 33799995
Stem Cell Res Ther. 2015 Sep 16;6:177
pubmed: 26377305
Int J Mol Sci. 2021 Oct 14;22(20):
pubmed: 34681739
Clin Exp Ophthalmol. 2019 Mar;47(2):274-285
pubmed: 30378239
J Transl Med. 2014 Oct 11;12:260
pubmed: 25304688
Cells Tissues Organs. 2018;206(3):119-132
pubmed: 30879015
Cureus. 2020 Nov 24;12(11):e11686
pubmed: 33391921